Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY: HIMS )

69.78 +11.28 (+19.28%)
Streaming Delayed Price Updated: 3:08 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
21 22 Next >
Hims & Hers Health Stock Is Sliding Thursday: What's Going On?
Hunterbrook releases a bearish report alleging that Hims & Hers sells knockoff GLP-1 weight loss drugs and relies on a single supplier with previously unreported ties to fraud and bankruptcy. 
Via Benzinga
Topics Fraud Supply Chain
Exposures Legal Supply Chain
Short Seller Hunterbrook Slams Hims & Hers (HIMS) Stock in New Report
HIMS stock is trading lower after Hunterbrook Media published a short report on the company, taking issue with its compounded GLP-1 drug. 
Via InvestorPlace
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
2 Top Growth Stocks to Buy With $500 Right Now
These top stocks have roaring growth stories to follow. 
Via The Motley Fool
Why Hims Is a 10x Stock
Disrupting the medical industry has enormous upside. 
Via The Motley Fool
Market Whales and Their Recent Bets on HIMS Options
Via Benzinga
8 Analysts Assess Hims & Hers Health: What You Need To Know
Via Benzinga
Looking Into Hims & Hers Health's Recent Short Interest
Via Benzinga
Looking At Hims & Hers Health's Recent Unusual Options Activity
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Should You Buy Hims & Hers Health Stock Right Now?
The telehealth company is offering innovative products at lower prices. 
Via The Motley Fool
Pre-Market Movers - June 21, 2024
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers. 
Via Talk Markets
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Shares of Eli Lilly stock are about to hit a new all-time high, sponsored by the pending approval of new weight loss drugs 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry. 
Via Benzinga
Smart Money Is Betting Big In HIMS Options
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Chart Of The Day: Hims & Hers Health - Good Growth In Good Sex
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. 
Via Talk Markets
3 Sector Stars Lead Growth: Foot Locker, Shake Shack, Hims & Hers
These three stocks are looking to get a chunk of the total added jobs in the economy, meaning that analyst double-digit upside and growth projections are real 
Via MarketBeat
Topics Economy
Exposures Economy
MarketBeat Week in Review – 6/3 - 6/7
Equity markets shrugged off a much hotter-than-expected jobs report, but there could be more volatility after the next readings on inflation come out next week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In May: Where Do Nvidia, Tesla, GameStop, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Kimberly-Clark To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments 
Via MarketBeat
Hims & Hers Health Stock Soared This Week: Here's Why
The company is still riding momentum from its recent weight loss drug announcement. 
Via The Motley Fool
SPDR ETF Report For Thursday, May 30
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Thursday, May 30. 
Via Talk Markets
Topics ETFs
Call Option Volumes Spiked For These 3 Stocks
Option traders decided to plow into call contracts for these three stocks, investors can see the specific fundamental reasons behind this decision 
Via MarketBeat
SPDR ETF Report For Wednesday, May 29
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Wednesday, May 29. 
Via Talk Markets
Topics ETFs
SPDR ETF Report For Tuesday, May 28
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Tuesday, May 28. 
Via Talk Markets
Topics ETFs
A New Name in Weight Loss Drugs
Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option. 
Via The Motley Fool
LifeMD Can Surge on Its GLP-1 Offerings
LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result 
Via MarketBeat
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.